Mantell Associates’ Post

#News: AbbVie has announced that it will be expanding its inflammatory and autoimmune disease portfolio by acquiring Landos Biopharma, Inc. for up to $212.5m. #Landos is a #clinicalstage #biopharmaceutical company that focuses on the development of #oraltherapeutics for patients with #autoimmunediseases. Inflammatory conditions such as #inflammatoryboweldisease (IBD) cause excess inflammation, while the body’s natural defence system mistakenly attacks normal cells as opposed to foreign cells in autoimmune diseases. In some conditions, including #rheumatoidarthritis and #lupus, both autoimmune and inflammatory diseases play a role when #antibodies get directed against the body’s own cells, causing inflammation. Under the terms of the agreement, #AbbVie will acquire Landos for approximately $137.5m, plus an additional $75m, subject to its achievement of a clinical development milestone. Meanwhile, AbbVie will gain rights to advance the clinical development of Landos’ lead investigational asset, NX-13, as a potential treatment for patients living with #ulcerativecolitis (UC) and #Crohnsdisease, two forms of IBD. Read more from PM LIVE 👇🏼 https://lnkd.in/gjEG_DW4

GSK and Chimagen Biosciences (Chimagen), a privately held biotechnology company, today announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialize CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases. #antibody #antibodies #mAb #mAbs #Biologics #Tcellengager #TCE #TCEs #SLE #LN #autoimmunediesease https://lnkd.in/e9nyVUjp

PharmaShots Weekly Snapshots recapitulate the highlights of the news covered throughout the week! Here's the weekly highlights of our daily news: AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia Kalaris Therapeutics Reverse Merges with AlloVir to Advance Therapies Focussing on Retinal Diseases BioNTech SE to Acquire Biotheus Inc., Enhancing its R&D Capabilities in Oncology and Expanding Reach Across China Schrödinger Enters into a Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis PTC Therapeutics, Inc. Reports the US FDA’s Accelerated Approval of its Gene Therapy for AADC Deficiency Happy Reading! Stay Tuned! Paratek Pharmaceuticals, RELIEF THERAPEUTICS Holding SA, Merck Group, AstraZeneca, Syros Pharmaceuticals, Structure Therapeutics, GSK, Johnson & Johnson, Autolus Therapeutics, Atamyo Therapeutics, argenx, Zai Lab, Caliway Biopharmaceuticals, Genascence Corporation, Actuate Therapeutics, Inc., Eisai US, Biogen, Regeneron, Sanofi, AlveoGene, Bristol Myers Squibb, ALTEOGEN Inc., Daiichi Sankyo US, IDEAYA Biosciences, Biocytogen, Apollo Therapeutics, Atsena Therapeutics, #Merck LaNova Medicines, Kalaris Therapeutics, AlloVir, Flare Therapeutics, Roche #news #weeklysnapshot #pharma #medtech #biosimilar #biotech #mergerandacquisition #clinicaltrial #digihealth #covid19 #animalhealth #regulatory #pharmashots

NImmune Biopharma, Inc celebrates AbbVie’s acquisition of Landos Biopharma and its lead clinical candidate NX-13. Terrific validation of TITAN-X, the A.I.-powered precision medicine platform and NImmune team that led the discovery and development of NX-13. NImmune founder and CEO Josep B. founded Landos in 2017 and led its successful growth to a publicly traded >$600M biopharma. TITAN-X, the computational platform that helped characterize the NLRX1 target also discovered NImmune’s best and first-in-class precision medicines, including omilancor, currently in a global Phase 3 program as a once daily oral for Ulcerative Colitis and other inflammatory and autoimmune diseases.    Today’s acquisition of Landos and NX-13 by Abbvie reinforces our pioneering work in immunometabolism in I&I and the novel immunoregulatory target discovery programs of the NIMML Institute, as well as the strong efficacy and safety profile of the first-in-class and best-in-class therapeutics we continue to develop at NImmune.   PR of today’s news: https://lnkd.in/gCHENN83  Learn more about NImmune here: https://nimmunebio.com/   #Biopharma #Immunology #DrugDevelopment #UlcerativeColitis

NImmune Biopharma, Inc's Founder, Chairman, President & CEO Josep B. shares his perspective on the recent AbbVie-Landos deal and the accelerating momentum in inflammation & immunology (I&I) drug development.   In this insightful op-ed published in BioSpace, Josep discusses the significance of the acquisition, Big Pharma's growing interest in novel I&I targets, and how AI-powered platforms like The NIMML Institute’s TITAN-X are transforming the discovery of next-generation precision medicines.   Read the full article to learn more about the immense potential in the I&I space and NImmune's role in advancing innovative therapies for patients in need: https://lnkd.in/gRmb78qx   #Biopharma #Immunology #DrugDevelopment #UlcerativeColitis #PrecisionMedicine

[Clinical Trials] 09/26 AbbVie's phase 3 TEMPO-1 Trial of Tavapadon for Early-Stage Parkinson's Disease Meets Primary Endpoint with Significant Reduction in MDS-UPDRS Score same day : ( ↓ NYSE: ABBV | -0.27% ) 09/26 Enanta Pharmaceuticals' phase 2a trial of EDP-323 shows reduction in viral load and clinical symptoms in RSV-infected adults same day : ( ↓ NASDAQ: ENTA | -0.19% ) 09/25 UNION therapeutics A/S' Orismilast Achieves Statistically Significant IGA0/1 Responses in Phase 2b Atopic Dermatitis Study, But Fails to Meet Primary EASI Endpoint 09/25 Celldex Therapeutics Reports 71% Complete Response in CSU Patients with Barzolvolimab in 52-Week Study at EADV Congress 2024 same day : ( ↓ NASDAQ: CLDX | -12.06% ) 09/25 LEO Pharma's DELTA FORCE trial reveals delgocitinib cream's superior efficacy over oral alitretinoin in severe chronic hand eczema 09/25 AbbVie Reports Efficacy of Upadacitinib in phase 3 Atopic Dermatitis Trials Over 16 Weeks same day : ( ↓ NYSE: ABBV | -1.15% ) 09/25 Genentech Reports phase III REGENCY Study Results: Gazyva with Standard Therapy Improves Renal Response in Lupus Nephritis Patients [Deals] 09/26 Biocon and Tabuk Pharmaceuticals Manufacturing Company team up to commercialize GLP-1 products for diabetes and weight management in the Middle East 09/26 Evaxion Biotech A/S and Merck & Co Sign a Option Agreement Worth Up to $1.2B for Preclinical Vaccine Candidates EVX-B2 and EVX-B3 same day : ( ↑ NASDAQ: EVAX | +7.42% ) ( ↓ NYSE: MRK | -1.2% ) 09/26 Evotec and Novo Nordisk join forces for stem cell-based therapy development, Novo gains exclusive rights to use outcomes same day : ( ↓ NYSE: NVO | -1.47% ) 09/26 Biogen Ends Collaboration with Sage Therapeutics on SAGE-324 Program After Negative phase 2 Trial Results same day : ( ↑ NASDAQ: SAGE | +1.0% ) ( ↑ NASDAQ: BIIB | +1.44% ) View the full newsletter contents for free via the link in the comments.

DelveInsight's analysis indicates that the global liver disease therapeutics market is expected to experience substantial growth, with North America projected to lead the market during the forecast period. The market is driven by advancements in treatment options and increasing patient needs. Key companies making notable progress in the liver disease therapeutics space include AbbVie, GSK, Bristol Myers Squibb, Abbott, Gilead Sciences, Astellas Pharma, Merck, Alnylam Pharmaceuticals, and Sanofi, among others. These companies are at the forefront of developing innovative treatments to address liver diseases. Get More Detailed Information: https://lnkd.in/gzr7pjpp #LiverDisease #HealthcareMarket #PharmaceuticalInnovation #DelveInsight #MarketAnalysis #Biopharma #LiverTherapeutics #Hepatology #DrugDevelopment #NorthAmerica #MedicalResearch #PharmaIndustry #ClinicalTrials #HealthcareInnovation #LiverHealth

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers: DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics … Continue reading → #PharmaceuticalsBiotech

Bronchopulmonary Dysplasia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers: DelveInsight’s, “Bronchopulmonary Dysplasia Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, … Continue reading → #PharmaceuticalsBiotech

Top 20 RNAi Therapeutic Companies of 2024 New-age therapeutics like RNAi have shown immense potential in shaping the future of the healthcare industry with advanced mechanisms of action. RNAi therapies show relatively low toxicity, making them safe, and highly effective medications. Like the previous year, Roche retains the topmost position with an R&D expenditure of $15.73B, followed by Novartis and AstraZeneca with $11.37B and $10.93B, respectively.  PharmaShots brings an illuminating report on the Top 20 RNAi Therapeutic Companies. To get a PDF copy of the report, reach out to us at [email protected] Roche Novartis AstraZeneca Eli Lilly and Company GSK Sanofi Moderna Novo Nordisk Amgen Takeda Regeneron Biogen BioNTech SE Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals Sarepta Therapeutics Jazz Pharmaceuticals Vir Biotechnology, Inc. Arrowhead Pharmaceuticals Arcturus Therapeutics #pharmashots #top20rnaicompanies #2023 #rnaitherapies #top20 #rna